NEUROCRINE BIOSCIENCES INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $NBIX in the last 30 days.
See all $NBIX insider activity →Neurocrine Biosciences (NBIX) began a Phase 2 trial for NBI-1117567, an Alzheimer’s drug candidate. The study will evaluate 135 adults with mild to moderate Alzheimer’s over 12 weeks. Primary efficacy is measured by changes in a Neuropsychological Test Battery composite score. Neurocrine aims to develop new treatments for Alzheimer’s disease.
Neurocrine Biosciences (NBIX) presented real-world data on congenital adrenal hyperplasia, showing varied and evolving impacts across patients' lifespans. The data highlighted diverse clinical needs and persistent treatment demands. The company suggests this could aid healthcare professionals in providing better support.
Needham reiterated a Buy rating on Neurocrine Biosciences with a $204 price target, suggesting a 49% upside from the latest close. The company's strong portfolio of FDA-approved treatments and promising pipeline were highlighted as key strengths.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning NBIX (NEUROCRINE BIOSCIENCES INC). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent NBIX coverage spans financial news, regulation and earnings.
The start of a Phase 2 trial adds clinical progress but also introduces execution risk; investors will watch for safety and early efficacy signals.
The data highlight unmet needs in adult patients and may influence future therapeutic positioning and reimbursement discussions.
Analyst upgrade and higher price target suggest bullish sentiment.
Potential negative sentiment and regulatory scrutiny could depress NBIX share price.
Expectation of another beat-and-raise sets up a positive skew into Q3 results.
AlphAI scores every news story that mentions NBIX with an AI model for sentiment and relevance, and aggregates insider trades from NEUROCRINE BIOSCIENCES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Neurocrine Biosciences (NBIX) began a Phase 2 trial for NBI-1117567, an Alzheimer’s drug candidate. The study will evaluate 135 adults with mild to moderate Alzheimer’s over 12 weeks. Primary efficacy is measured by changes in a Neuropsychological Test Battery composite score. Neurocrine aims to develop new treatments for Alzheimer’s disease.
2 min readNeurocrine Biosciences (NBIX) presented real-world data on congenital adrenal hyperplasia, showing varied and evolving impacts across patients' lifespans. The data highlighted diverse clinical needs and persistent treatment demands. The company suggests this could aid healthcare professionals in providing better support.
1 min readNeedham reiterated a Buy rating on Neurocrine Biosciences with a $204 price target, suggesting a 49% upside from the latest close. The company's strong portfolio of FDA-approved treatments and promising pipeline were highlighted as key strengths.
1 min readPatient advocates and experts raise concerns over safety issues with Neurocrine Biosciences' drug Vykat XR, approved for Prader-Willi syndrome. The drug has been linked to seven deaths and nearly 100 hospitalizations since its approval 18 months ago, though regulators note no proven causality. Some experts believe the evidence shows unacceptable harm.
2 min readTruist Securities previewed Q3 2026 earnings for eight biotech companies, highlighting Insmed (INSM), BridgeBio (BBIO), and Neurocrine (NBIX) for potential volatility. Insmed's Brinsupri forecast was reduced due to lower prescription trends. BridgeBio's revenue surged 202% to $713M with 94% gross margins. The FDA accepted BridgeBio's NDA for infigratinib, with analysts maintaining Buy ratings and price targets.
7 min readNeurocrine Biosciences (NBIX) CMO Eiry Roberts reported holding 51,331 shares as of September 28, 2026, including 50,146 shares held in trust. The report also lists options and restricted stock units with vesting dates through 2029, including 60,005 shares at a $79.02 exercise price.
1 min readWall Street analysts issued research calls on several companies, including upgrades for BorgWarner (BWA), Boyd Gaming (BYD), JetBlue (JBLU), Procter & Gamble (PG), and XP (XP), and downgrades for Gentex (GNTX), Goosehead Insurance (GSHD), Nike (NKE), PTC (PTC), and RXO (RXO). New coverage was initiated for Lattice Semiconductor (LSCC), Lockheed Martin (LMT), Northrop Grumman (NOC), Neurocrine Biosciences (NBIX), and SPX Technologies (SPXC).
3 min readJuan Andres will return from retirement to serve as COO of Moderna, effective October 5. Meanwhile, Pharming's CEO has departed following disagreements with the board. Neurocrine has also announced a leadership change.
1 min readUBS reduced its price target for Neurocrine Biosciences (NBIX) to $214 from $231, citing competition and safety concerns. The stock trades at 11x 2027 P/E, with a 14% EPS CAGR. Q2 sales for Ingrezza and Crenessity exceeded estimates. Other analysts maintain Buy ratings, but Vykat faces safety scrutiny.
2 min readNEUROCRINE BIOSCIENCES INC (NBIX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 28, 2026, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc. (the “Company”) appointed Eiry
1 min read
